BioMerieux ( BioMerieux)

Primary tabs

BioMerieux's picture

Management

Contact Address

About BioMerieux

bioMérieux (Euronext: BIM) is a multinational biotechnology company founded and headquartered in France. A world leader in the field of in vitro diagnostics for 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors.

BioMerieux press release, blog etc

Mon, 01/13/2025 - 17:03 bioMerieux to present at the 43rd Annual J.P. Morgan HealthCare Conference
Fri, 05/24/2024 - 04:45 Malawi Ministry of Health, bioMerieux, and Pfizer Form Countrys First Multisectoral Collaboration to Help Address Antimicrobial Resistance
Wed, 05/18/2022 - 04:00 Closing of the acquisition of Specific Diagnostics
Tue, 04/12/2022 - 13:27 bioMerieux strengthens its commitment to fight antimicrobial resistance with the acquisition of Specific Diagnostics, an innovative company focusing on fast AST solution
Thu, 01/06/2022 - 05:53 French multidisciplinary consortium ARPEGE awarded public funding of close to 9 million to fight antibiotic resistance
Tue, 12/14/2021 - 08:33 Corporate Social Responsibility: bioMerieux recently received a series of official recognitions from independent third parties
Wed, 10/20/2021 - 19:45 Baxter and bioMerieux announce CE mark for NEPHROCLEAR CCL14 test to predict persistent severe acute kidney injury
Tue, 06/29/2021 - 04:53 In the fight against Antimicrobial Resistance, bioMerieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL Rapid AST system in Europe
Thu, 06/24/2021 - 13:32 bioMerieux launches EPISEQ SARS-COV-2, a cloud-based software application for the epidemiological surveillance of SARS-CoV-2 variants
Thu, 06/24/2021 - 04:08 bioMerieux announces the CE marking of the new generation semi-quantitative VIDAS SARS-COV-2 IgG II serology test.
Tue, 06/22/2021 - 13:28 A survey in 5 European countries about sepsis demonstrates the lack of awareness and an expectation for faster diagnostic capabilities
Wed, 04/07/2021 - 01:53 bioMerieux announces the CE marking of 3 dengue immunoassays on VIDAS
Wed, 02/03/2021 - 08:51 bioMerieux announces the CE marking of NEPHROCHECK test on VIDAS
Wed, 10/14/2020 - 06:00 bioMerieux announces the CE marking of TB IGRA test on VIDAS
Tue, 06/30/2020 - 18:34 Information concerning 2019 dividend and the bioMerieux General Shareholders Meeting
Thu, 05/21/2020 - 18:45 CE marking of bioMerieux serology tests for SARS-CoV-2 on VIDAS
Wed, 05/06/2020 - 03:44 Serology tests for SARS-CoV-2 on VIDAS undergo validation preceding imminent launch
Tue, 03/24/2020 - 03:03 bioMerieux receives Emergency Use Authorization for BIOFIRE COVID-19 test